effect of unani formulation in lump in breast.

A CLINICAL STUDY ON THE MANAGEMENT OF SALA-E-SADI (FIBROADENOMA OF BREAST) WITH UNANI FORMULATION-AN OPEN LABEL SINGLE ARM TRIAL - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/02/104540

Enrollment

Registered

2026-02-23

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D249- Benign neoplasm of unspecified breast

Interventions

Intervention1: For Local Application 1.Tukhm Krafs(Apium graveolens) 2.Babuna(Matrica chamomilla) 3.Mako(Solanum nigrum) 4.Nakhoona(Trigonella uncata) For Oral 1.Aftemoon (Cuscuta reflexa) 2.Bisfaij(

Eligibility

Inclusion criteria

Inclusion criteria: Women of age group 15-40 years Lumps size of 3 cm or less. Upto BI RADS 2. Married and unmarried both Patient able to participate in the study and ready to follow the instruction and signed the informed consent.

Exclusion criteria

Exclusion criteria: Patient with h/o severe systemic diseases-DM, HIN, IHD, Renal disease. Women below 15yrs and more than 40yrs of age. BI RADS 0 & BI RADS 3 and above Patient with h/o malignancy. Pregnant and lactating women. Patients on hormonal therapy. Patient not following instruction.

Design outcomes

Primary

Measure	Time frame
Change in fibroadenoma size before and after treatment.Timepoint: At baseline & at every 15th day till 90 days	—

Secondary

Measure	Time frame
Improvement in symptoms (pain)Timepoint: At baseline & at every 15th day till 90 days	—

Countries

India

Contacts

Public ContactDr Aysha Raza

Ayurvedic and Unani Tibbia College and Hospital

draysharaza11@gmail.com9354925031

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026